CStone Pharmaceuticals (Suzhou) Co., Ltd
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From CStone Pharmaceuticals (Suzhou) Co., Ltd
Despite a pending domestic approval for BioNTech/Fosun's COVID-19 vaccine, China’s apparent belief in another, domestically developed, mRNA vaccine sees a large group of investors pour hundreds of millions into a little-known private bioventure founded by an ex-Moderna scientist and poised to take on the US biotech.
Also, deals involving Sumitomo Dainippon, Tolero, Boston Biomedical, Zai Lab, Turning Point, SciClone, EpicentRx, Yuhan, GI Innovation, Takeda, Carmine, HitGen, Morphic, CStone and Burning Rock.
Amid a sweeping National Security Law passage, many biotech and healthcare firms from China opt for a Hong Kong initial public offering in the meanwhile appetite for a US listing wanes.
A new national security law passed by China is expected to bring an uncertain future to many health companies eyeing a possible listing in Hong Kong.
- Large Molecule
- Other Names / Subsidiaries
- CStone Pharmaceuticals